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Introduction
Alzheimer's disease is a common degenerative disease in the elderly. The aetiology of Alzheimer's disease is considered as multifactorial and includes oxidative stress, neuroinflammation and synaptic failure (Querfurth and LaFerla, 2010) . Histopathological lesions include senile plaques, which are composed mainly of amyloid-b protein, and neurofibrillary tangles due to abnormal phosphorylated tau protein levels (Roland and Helmut, 2009) . As amyloid-b remains one of the diagnostic biomarkers that differentiates Alzheimer's disease from other dementias (Jack et al., 2018) , targeting amyloid-b or BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) has become an important therapeutic approach (Graham et al., 2017) .
BACE1 is the rate-limiting enzyme for amyloid-b generation (Vassar et al., 2009) . Although BACE1 deficiency rescues cognitive impairment in animal studies (Ohno et al., 2004; Hussain et al., 2007; Hu et al., 2018) , selective BACE1 inhibitors have failed in clinical trials to date (Hawkes, 2017; Zhu et al., 2018) . Evidence has suggested that BACE1 has more than 40 membrane protein substrates and plays an important role in synaptic plasticity and cognitive function (Filser et al., 2015; Zhu et al., 2018) ; therefore, complete BACE1 inhibition might cause harmful side effects (Menting and Claassen, 2014) . Due to the multifactorial aetiology of Alzheimer's disease, inhibiting BACE1 may still not be enough to halt disease progression (Scheltens et al., 2016) . It remains unclear whether BACE1 inhibitors would be ultimately beneficial for patients with Alzheimer's disease (Graham et al., 2017; Coimbra et al., 2018) .
Current ongoing clinical trials are focused on inflammation, neuroprotection and neurotransmitters, among others. Disease-modifying therapy has emerged as an alternative strategy (Cummings et al., 2017) . It is worth noting that BACE1 deregulation is closely associated with disease mechanisms (Chami and Checler, 2012) . For example, in reactive astrocytes triggered by neuroinflammation, Bace1 transcription is enhanced (Frost and Li, 2017) . Oxidative stress markers that contribute to cell death are positively correlated with BACE1 activity (Tamagno et al., 2002; Chami and Checler, 2012) . Calcium disturbances also activate Bace1 transcription (Kusakawa et al., 2000; Wen et al., 2008) . Interestingly, in Alzheimer's disease brains, BACE1 protein levels, but not mRNA levels, are significantly increased (Holsinger et al., 2002; Preece et al., 2003; Yang et al., 2003) , highlighting the importance of post-transcriptional mechanisms in the pathophysiology of Alzheimer's disease (Sun et al., 2012) . In this respect, identifying the potential mechanisms that regulate BACE1 at the translational level might provide an alternative strategy for understanding and treating Alzheimer's disease.
MMP13 (matrix metallopeptidase 13, or collagenase 3) is located primarily in the extracellular matrix (ECM) (Huntley, 2012) . It has been reported that MMP13 plays a key role in bone metabolism and cartilage homeostasis, as well as in tumour invasion and metastasis (Leeman et al., 2002; Li and Johnson, 2011) . The substrates of MMP13 include type I-IV collagen and perlecan (Leeman et al., 2002) , which are major components of the basement membrane that play a key role in neurological diseases (Wlodarczyk et al., 2011; Yurchenco, 2011) . Early changes in the ECM have been identified in Alzheimer's disease (Lepelletier et al., 2017) , but direct evidence of the involvement of MMP13 is lacking. Descriptive studies have shown that MMP13 is increased in ischaemic brains (Cuadrado et al., 2009) and in microglia treated with amyloid-b (Ito et al., 2007) .
The current study offers new insights into the translational regulation of BACE1 through MMP13 signalling and provides evidence that reducing BACE1 protein levels instead of completely inhibiting BACE1 represents an alternative strategy for Alzheimer's disease treatment.
Materials and methods
Reagents and cell culture MMP13 inhibitors WAY170523 (Tocris Bioscience), CL82198 (Cayman) and SC205756 (Santa Cruz Biotechnology), FGF/ PDGF/VEGF RTK inhibitor 341610 (Merk Millipore), PI3 kinase inhibitors LY294002 (Sigma Aldrich), eIF4E/eIF4G interaction inhibitor 4EGI1 (Selleck), protease inhibitor MG132 (Sigma), the transcriptional inhibitor actinomycin D (ActD, Sigma) and protein biosynthesis inhibitor cycloheximide (CHX, Sigma) were dissolved in dimethyl sulphoxide (DMSO) and lysosomal inhibitor chloroquine (CQ, Sigma) was dissolved in sterilized double-distilled H 2 O. The ultimate concentration of DMSO was not more than 1:2000. All chemicals were used in the concentrations and treatment time indicated in the figure legends.
Cell lines of HEK293 (human embryonic kidney), SH-SY5Y (human neuroblastoma) and HT22 (mouse hippocampal neuron) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with 10% foetal bovine serum (FBS, Gibco) and 100 U/ml penicillin and 100 mg/ml streptomycin. HEK293 cells stably expressing amyloid-b precursor protein (HEK-APP) were cultivated in complete DMEM with 200 mg/ml G418. After treatment with CL82198, the conditioned media was collected and cleared by centrifugation at 12 000g for 20 min at 4 C to remove cellular debris. Primary cortical neurons were prepared from SpragueDawley rat embryos at Day 17-18 and treated with 0.25% trypsin for 15 min as described previously (Zha et al., 2017) . In brief, digested tissues were dissociated by trituration and plated on a 6-well plate at a density of 1.0 Â 10 6 cells/well, and the cultures were maintained in DMEM for 24 h. Subsequently, the medium was replaced with fresh Neurobasal TM medium (Invitrogen) supplemented with 2% B27 (Invitrogen). Half of the medium was removed and replenished with the fresh Neurobasal TM medium every 2-3 days. Neurons were treated with 0.1, 0.5, 1, 2, 5 and 10 mM SC205756 for 48 h. All procedures were carried out in accordance with the Chongqing Medical University guidelines for the care and use of laboratory animals. All cells were incubated at 37 C and 5% CO 2 .
Gene constructs and RNA interference
Human pCMV-eIF4B (eukaryotic translation initiation factor 4B) plasmid was purchased from Origene. S422R mutation was made using Mut Express MultiS Fast Mutagenesis Kit (Vazyme). Primer sequences were: F: 5 0 -GGACAGGAAGGGA GTCATCACAAACTGGGACCTCCACCAC-3 0 , and R: 5 0 -G TGATGACTCCCTTCCTGTCCTCGACCGTTCCCGTTCCT-GA-3 0 . Human pcDNA4-BACE1 plasmid containing the entire human BACE1 coding region but did not contain 5 0 UTR (À5 0 UTR) was acquired from Dr W.H. Zhou (Chongqing Medical University). pcDNA4-BACE1/+5 0 UTR containing the 5 0 UTR of BACE1 (NM_012104) was amplified and cloned into pcDNA4 vector using the following primers: F: 5 0 -CCG CTCGAGTCCCCAGCCCGCCCGGGAGCT-3 0 , R: 5 0 -CCGGA ATTCGGTGGGCCCCGGCCTTCGGG-3 0 . The restriction sites were XhoI and EcoRI (Lammich et al., 2004) . All constructs were confirmed by DNA sequencing (Zhu et al., 2012) . pCMV6-MMP13 was purchased from Origene. Transient transfections were performed using Lipofectamine TM 2000 (Invitrogen). Lentiviral particles bearing Mmp13 shRNA were purchased from GeneChem. The following Mmp13 shRNA sequences were used: Mmp13 shRNA-1: 5 0 -GAGCACTACTTGAA ATCAT-3 0 (Meierjohann et al., 2010) and Mmp13 shRNA-2: 5 0 -GUGACCUUAUGUUUAUCUU-3 0 (NM_008607). The siRNA oligonucleotides for human BACE1 were synthesized by Shanghai GenePharma Co. Ltd, and the non-targeting control siRNA (NC) was used as the negative control. The following siRNA oligonucleotides were used: siBACE1-1 (5 0 -UGGACUGCAAGGAGUACAAtt-3 0 ), siBACE1-6 (5 0 -GACUG UGGCUACAACAUUCtt-3 0 ) (Singer et al., 2005) and NC (5 0 -UUCUCCGAACGUGUCACGUtt-3 0 ). HEK293 cells were transfected with 60 nM siRNAs for 6 h using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's protocol. Forty-eight hours after transfection, inhibition of target genes was confirmed by western blotting.
Luciferase activity assay
HEK293 cells were seeded onto 96-well plates for 24 h before transfection. Cells were then transiently transfected with 200 ng luciferase reporter plasmid bearing 758 bp (À691 to + 67) nucleotides of human BACE1 promoter (pGL4.21-BACE1) or empty plasmid pGL4.10 (a negative control, driven by SV40, Promega) using Lipofectamine TM 2000 according to the manufacturer's instructions. Twenty-four hours after transfection, cells were treated with 5 mM CL82198 or 10 nM WAY170523 for 48 h, and DMSO was used as a negative control. The luciferase activities were measured using a luciferase assay kit (Promega) according to the manufacturer's instructions and the relative fold changes of luciferase activity were normalized to pGL4.10 as internal standard. 
Human brain tissues

Animal treatment and protein preparation
All protocols were approved by the Commission of Chongqing Medical University for ethics of experiments on animals and were conducted in accordance with international standards. APPswe/PS1E9 transgenic mice (APP/PS1, B6C3) were obtained from Jackson Laboratory imported by Nanjing University (#004462). Controls were generated from littermates that did not have Alzheimer's disease phenotype. Sixmonth-old mice were intraperitoneally injected with CL82198 (10 mg/kg) or saline every other day for 2 months . For the Mmp13 shRNA experiment, mice at 7 months of age were anaesthetized with 10% chloral hydrate (50 mg/kg, i.p.) before being mounted on a stereotaxic apparatus, and the cannulas (30-gauge stainless steel tubing) were implanted into the hippocampus (anterior-posterior: À2.0 mm, medial-lateral: AE 1.5, dorsal-ventral: À2.0 mm). After 7 days recovery, 2 ml lentivirus particles (1.5 Â 10 12 viral genomes/ ml) were injected into the hippocampus bilaterally at a rate of 0.1 ml/min (Hsiao et al., 2014) .
Mice were euthanized with isofluorane anaesthesia and then transcardially perfused with ice-cold phosphate-buffered saline (PBS). Brains were rapidly isolated and sonicated in RIPA buffer (Cell Signaling Technology). Soluble extracellular proteins were collected from homogenized lysates after centrifugation at 16 000g for 1 h at 4 C. The supernatants were used for analyses of secreted APP forms (sAPP/b). Pellet was used for insoluble material extraction using 70% formic acid (Sigma) as described previously (Zhu et al., 2011; Obregon et al., 2012) . For total protein extraction, cells or brain tissues were homogenized in ice-cold lysis buffer [50 mM Tris-HCl, pH 8.0, 140 mM NaCl; 1.5 mM MgCl 2 ; 0.5 % NP-40 with complete protease inhibitor cocktail (Roche)]. Samples were sonicated on ice and centrifuged at 16 000g for 10 min. Protein concentration was measured in the supernatant by BCA Protein Assay (Dingguo).
Western blotting assay
Following the sample preparation as described above, protein samples were separated on 8% SDS-PAGE or 16.5% Tris-tricine gels [for C-terminal fragment (CTF)], and were transferred onto 0.45-mm or 0.22-mm (for CTF) PVDF membranes (Millipore). The monoclonal or polyclonal antibodies used were BACE1 (Abcam, 1:1000); APP-full length and b-CTF, -CTF (A8717, Sigma, 1:3000); sAPP (6E10, Covance, 1:1000); sAPPb (Covance, 1:500); ADAM10 (Abcam, 1:1000); phospho-eIF4B (Ser422) (Cell Signaling Technology, 1:1000); eIF4B (Proteintech, 1:2000) ; MMP13 (Santa Cruz, 1:500); PSEN1 (Proteintech, 1:500); neprilysin (Proteintech, 1000); IDE (Proteintech, 1:1000); phospho-Akt (Ser473) (Proteintech, 1:500); Akt (Proteintech, 1:1000); PI3K (phosphatidylinositide 3-kinase; Proteintech, 1:500); GAPDH (Proteintech, 1:10 000); b-actin (Proteintech, 1:2000) . The secondary antibodies were goat anti-rabbit or anti-mouse horseradish peroxidase-labelled antibodies (Proteintech, 1:5000). The membranes were visualized using an ECL reagent (Thermo) and a Fusion FX5 image analysis system (Vilber Lourmat). Relative protein intensities were calculated using Quantity One Õ software (Bio-Rad).
Quantitative real-time polymerase chain reaction
Total RNA from cells or tissues was extracted using TRIzol Õ reagent (Invitrogen). First-strand cDNA was generated using 1 mg of total RNA with reverse transcriptase kit (TaKaRa). The mRNA expression of human BACE1 or mouse Mmp13 was detected by quantitative real-time PCR (qPCR) with SYBR Õ Premix Ex Taq TM II (TaKaRa) on an Eppendorf detection system (Fan et al., 2016) . The reaction mixture (20 ml total) consisted of 10 ml 2Â SYBR Õ mix, 8 ml nuclease-free water, 0.5 ml of primers (human BACE1, F:
0 ) and 1 ml diluted cDNA. The reactions were performed as follows: 95 C for 30 s, followed by 40 cycles of 95 C for 5 s and 60 C for 34 s. After the reactions were completed, the temperature was increased from 60 C to 95 C to obtain the melting curve. Actb (b-actin) was used as an internal control.
ELISA
Soluble and insoluble amyloid-b 40 and amyloid-b 42 or PI3K activity were measured by sandwich ELISA using commercially available kits (Cusabio).
Morris water maze
The Morris water maze test included four platform trials per day for five consecutive days, and a probe trial on the sixth day. In the platform trials, each mouse was allowed 60 s to find the platform. If the mouse could not locate the platform, we guided it to the platform and allowed it to rest there for 15 s. The escape latency was measured. In probe trials, the platform was removed, and each mouse was given 60 s to locate where the platform was originally placed. Performance was video-recorded and analysed by image analysing software (ANY-maze, Stoelting). Data were analysed by two-way ANOVA, followed by Tukey's post hoc test.
Contextual and cued fear conditioning
Mice were tested in a 3-day paradigm as described previously (Cheng et al., 2014) . On the first day, the mice were placed in the training chamber to acclimate for 120 s, then they were presented with a 30 s pure tone (2800 Hz, 85 dB, 30 s) that co-terminated with 2 s foot shock (0.45 mA). This procedure was repeated three times with an intertrial interval of 120 s. On the second day, the mice were returned to the training chamber for 10 min without exposure to either the tone or foot shock, to measure contextual freezing. On the last day, the mice were placed in the training chamber for 120 s, then presented with a 30 s pure tone (2800 Hz) without the 2 s foot shock. Behaviour was recorded by video camera and freezing data were measured using FreezeScan software.
Immunohistochemistry
Hemibrains were drop-fixed in 4% paraformaldehyde. Frozen parasagittal sections (30 mm) from cryopreserved brains were cut using a sliding microtome. Sections were stained with antiamyloid-b antibody (6E10) or ionized calcium-binding adaptor molecule 1 (Iba1, Proteintech) antibody, developed by DAB immunohistochemistry (Zhongshan Golden Bridge), counterstained with haematoxylin. The total number of 6E10-or Iba1-positive plaques in each section was quantified by ImageJ software and the average number of plaques per section was calculated (8-11 sections/mouse). The total number of plaques in the sections from each mouse were then visually counted at low magnification with a microscope and plaque numbers were calculated .
Statistical analysis
All data are presented as the mean AE SEM from three independent experiments. The statistical comparisons between the two groups were tested using Student's t-test. The comparisons among groups were tested using one-way or two-way analysis of variance (ANOVA).
Data availability
The data that support the findings of present study are available from the corresponding author on reasonable request.
Results
CL82198, a specific MMP13 inhibitor, reduces BACE1 protein levels
As shown in Fig. 1A , HEK293 cells transiently transfected with the BACE1 promoter showed a dramatic increase in luciferase activity compared with those transfected with the plasmid vector pGL4.10. Two MMP13 inhibitors, WAY170523 and CL82198, significantly decreased BACE1 promoter-driven luciferase activity without having an effect on cells transfected with pGL4.10. Western blotting analysis showed that BACE1 protein levels were dramatically decreased when BACE1 was knocked down with siRNA, indicating that the BACE1 antibody was specific for BACE1 at $70kD (Fig. 1B) . As expected, WAY170523 significantly decreased BACE1 protein levels in HEK293 cells (Fig. 1C) . Because WAY170523 may inhibit MMP1 and MMP9 (Li and Johnson, 2011) in addition to MMP13, we determined whether CL82198, which does not have an effect on MMP1 and MMP9 (Chen et al., 2000; Li and Johnson, 2011; Wang et al., 2013) , could also reduce BACE1 levels. As shown in Fig. 1D and E, CL82198 reduced BACE1 protein levels starting at 24 h of treatment at concentrations ranging from 1 mM to 10mM in SH-SY5Y (human neuroblastoma) cells. We then tested whether the direct manipulation of MMP13 could affect BACE1 protein expression. As shown in Fig. 1F , an MMP13-neutralizing antibody decreased BACE1 protein levels in SH-SY5Y cells. In addition, Mmp13 knockdown with two different shRNAs in HT22 (mouse hippocampal) cells and MMP13 overexpression in HEK293 cells led to a significant decrease and increase of BACE1 protein levels, respectively (Fig. 1G-I ). To validate that MMP13 indeed mediates the effects of CL82198 on BACE1 further, we next carried out a rescue experiment. As shown in Fig. 1J , the effect of CL82198 on BACE1 protein expression could be diminished by overexpressing MMP13 in HEK293 cells. It has been reported that another reagent, SC205756 [pyrimidine-4,6-dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide)], also exhibits MMP13 inhibitory effects (Nishimura et al., 2012; Duncan et al., 2016) . Thus, we further assessed the effects of SC205756 on BACE1. Indeed, in primary cultured neurons (Fig. 1K ) and HEK293 cells (Fig. 1L ), SC205756 significantly reduced BACE1 protein expression. As BACE1 is a key enzyme in APP processing, we next examined whether CL82198 may be functional in APP proteolysis. In HEK-APP cells incubated with CL82198 for 48 h, soluble APPb (sAPPb) levels were significantly reduced, while APP and ADAM10 levels were not altered (Fig. 1M) . These results indicated that MMP13 effectively regulated BACE1 protein expression in multiple cell lines and primary neurons and that the effect of CL82198 was mediated by MMP13.
PI3K signaling is involved in MMP13-mediated regulation of BACE1
MMP13 is known to promote receptor tyrosine kinase (RTK)-driven migration in melanocytes and melanoma cells (Meierjohann et al., 2010) . Studies have also demonstrated that RTK-PI3K signalling regulates a variety of cellular functions, including differentiation, survival and motility (Nakada et al., 2013; Hevner, 2015; Regad, 2015) . To determine whether RTK-PI3K is involved in the MMP13-mediated regulation of BACE1 protein expression, we first assessed the effect of 341610, an FGF/PDGF/ VEGF RTK inhibitor (Renhowe et al., 2009) , in SH-SY5Y cells. As shown in Fig. 2A , 341610 treatment alone significantly reduced the basal protein levels of BACE1. In the presence of 341610, BACE1 inhibition by CL82198 was attenuated. Rescue experiments further showed that in SH-SY5Y cells treated with 341610, BACE1 protein levels were significantly increased by MMP13 overexpression, which also attenuated the effect of CL82198 (Fig. 2B) . MMP13 seemed to directly activate PI3K signalling because PI3K activity (Fig. 2C ) and phospho-Akt (p-Akt) levels (Fig. 2D) were significantly higher in MMP13-overexpressing cells than in vehicle control cells. Treatment with 341610 reduced PI3K activity and p-Akt under control conditions and attenuated the effect of MMP13 on PI3K/ p-Akt ( Fig. 2C and D) . Consistently, treatment with the PI3K inhibitor LY294002 alone significantly reduced BACE1 protein levels and diminished the effect of CL82198 on BACE1 (Fig. 2E ). In the presence of LY294002, MMP13 overexpression reversed the downregulation of BACE1, and the effect of CL82198 on BACE1 was attenuated (Fig. 2F) . These results indicated that RTK-PI3K signalling was involved in MMP13-mediated BACE1 protein regulation.
Reduced BACE1 protein levels may result from gene transcription inhibition, protein degradation enhancement or protein synthesis reduction. Thus, we determined whether BACE1 was controlled at the transcriptional level. As shown in Fig. 2G , CL82198 or the PI3K inhibitor LY294002 failed to alter BACE1 mRNA levels. Similarly, Bace1 mRNA was not altered by Mmp13 knockdown (Fig.  2H) . It was also unlikely that the BACE1 reduction by CL82198 was mediated by protein degradation machinery because neither the proteasomal inhibitor MG132 (Zhan et al., 2016) nor the lysosomal inhibitor chloroquine (CQ) (Yang et al., 2011) blocked the effect of CL82198 on BACE1 (Fig. 2I and J) . To test whether protein synthesis might be involved, we assessed the effect of the protein synthesis inhibitor cycloheximide (CHX) on BACE1 protein expression, and the transcriptional inhibitor actinomycin D (ActD) was used as a control. As shown in Fig. 2K , although basal protein levels of BACE1 were significantly Cell lysates were prepared and subjected to western blotting analysis for APP and ADAM10. sAPPb was analysed in conditioned media using an sAPPb antibody. All values were normalized to CTRL or MOCK (1.0) within each experiment. The error bars are the SEM. n.s. = no significant difference; *P 5 0.05, **P 5 0.01, ***P 5 0.001 (ANOVA, n = 3 or 4).
decreased in cells treated with ActD or CHX, the effect of CL82198 on BACE1 was diminished in only the presence of CHX. These results suggested that MMP13 might not regulate BACE1 transcription or protein degradation. Instead, BACE1 protein synthesis was affected by MMP13. eIF4B phosphorylation at S422 mediates regulation of BACE1 by MMP13
It has been reported that translation initiation is a ratelimiting step in protein synthesis, which involves a variety of eukaryotic translation initiation factors (Sonenberg and . All values were normalized to CTRL (1.0) within each experiment. The error bars are the SEM. n.s. = no significant difference; *P 5 0.05, **P 5 0.01, ***P 5 0.001 (ANOVA, n = 3 or 4).
Hinnebusch, 2009). Among these, eIF4E and eIF4G join the eIF4F complex and facilitate cap-binding (Sonenberg and Hinnebusch, 2009; Bitterman and Polunovsky, 2012) . Interestingly, eIF4B at serine 422 (S422) can be phosphorylated by PI3K (Raught et al., 2004; Shahbazian et al., 2010; Parsyan et al., 2011) , suggesting an important role of eIF4B phosphorylation in PI3K signalling. Thus, we first tested the effect of the translation inhibitor, 4EGI1, which disrupts the eIF4E-eIF4G interaction (Moerke et al., 2007; Bitterman and Polunovsky, 2012) , on BACE1 protein expression. As shown in Fig. 3A , the administration of 4EGI1 significantly reduced BACE1 protein levels in SH-SY5Y cells, which further diminished the effect of CL82198 on BACE1. We then tested whether eIF4B activity was controlled by MMP13. As shown in Fig. 3B , CL82198 at 1-10 mM inhibited eIF4B phosphorylation at S422 (p-eIF4B). Consistently, MMP13 overexpression significantly increased p-eIF4B levels, which were significantly attenuated in the presence of the PI3K inhibitor LY294002 (Fig. 3C) . Conversely, Mmp13 knockdown led to a significant decrease in p-eIF4B levels (Fig. 3D) . These results suggested that eIF4B activity might link MMP13 with PI3K signalling.
To determine whether eIF4B phosphorylation is involved in CL82198/MMP13-mediated BACE1 regulation, we compared the effect of CL82198/MMP13 in cells overexpressing wild-type eIF4B and mutated eIF4B at 422 (S422R). As shown in Fig. 3E , eIF4B overexpression significantly increased BACE1 protein levels compared with S422R overexpression. S422R but not eIF4B attenuated the effect of CL82198 on BACE1 protein. We also found that in cells overexpressing MMP13, the presence of S422R, but not eIF4B, resulted in significantly reduced BACE1 levels (Fig.  3F) . It has been reported that BACE1 translation is dependent on the 5 0 UTR (Pestova and Kolupaeva, 2002; Dmitriev et al., 2003; Rossner et al., 2006) . To validate whether the function of eIF4B was also dependent on the BACE1 5 0 UTR, we assessed the effect of CL82198 and eIF4B mutants on cells transfected with BACE1 constructs with 5 0 UTR either included ( + 5 0 UTR) or deleted (À5 0 UTR). As shown in Fig. 3G , basal BACE1 protein levels were dramatically lower in cells overexpressing the + 5 0 UTR construct than in cells overexpressing the À5 0 UTR construct, consistent with previous findings (Lammich et al., 2004; Mihailovich et al., 2007) . In the presence of the + 5 0 UTR but not the À5 0 UTR, CL82198 significantly decreased BACE1 protein levels, indicating that the CL82198 regulation of BACE1 was mediated by the 5 0 UTR (Fig. 3H) . Similarly, eIF4B's regulation of BACE1 was also dependent on the 5 0 UTR in BACE1 mRNA, as S422R reduced BACE1 protein levels in only the + 5 0 UTR-expressing cells (Fig. 3H) . These results indicated that eIF4B phosphorylation at S422 mediated the regulation of BACE1 by MMP13, and the 5 0 UTR-dependence further supported a translational mechanism.
Mmp13 knockdown or CL82198 reduces Alzheimer's diseaseassociated pathology in APP/PS1 mice We found that MMP13 and PI3K expression levels were significantly increased in the brains of patients with Alzheimer's disease (Fig. 4A) . Based on the finding that MMP13 inhibition by CL82198 reduced BACE1 protein levels in cultured cells, we speculated that Mmp13 knockdown or CL82198 treatment would reduce Alzheimer's disease-associated pathology in the brains of APP/PS1 mice. Thus, we first assessed the effect of Mmp13 knockdown on hippocampal amyloid-b deposition using a 6E10 antibody that recognizes all amyloid-b species (Sarsoza et al., 2009; Kim et al., 2015) . As shown in Fig. 4B , Mmp13 knockdown significantly decreased the number of plaques in APP/ PS1 mice. Interestingly, MMP13 protein levels were also significantly increased in the hippocampi of APP/PS1 mice (Fig. 4C and D) , suggesting that MMP13 is involved in Alzheimer's disease-associated pathology.
To investigate whether the reduced amyloid-b load was associated with BACE1 and APP processing, we assessed the effect of Mmp13 knockdown on APP and BACE1, as well as ADAM10 (a disintegrin and metalloproteinase domain 10) and presenilin 1 (PSEN1), which are also involved in the regulation of amyloid-b generation (Vincent and Checler, 2012) . As shown in Fig. 4C , hippocampal Mmp13 knockdown caused significant reductions in BACE1 levels in wild-type and APP/PS1 mice, while APP, ADAM10 and PSEN1 levels were not altered; these data are consistent with the in vitro findings that BACE1 was selectively regulated by MMP13. As BACE1 is involved in APP processing and amyloid-b generation, we then assessed the levels of soluble APPb (sAPPb), sAPP and the CTF of APP. Similar to BACE1 changes, sAPPb and b-CTF levels were significantly reduced in wild-type and APP/PS1 mice, while sAPP levels were significantly increased (Fig. 4C) . The effect of Mmp13 knockdown was further validated by the second Mmp13 shRNA (shMMP13-2), which similarly reduced BACE1 protein levels in wild-type and APP/PS1 mice (Fig. 4D) . The effect of Mmp13 knockdown on amyloid-b generation was further assessed. As shown in Fig. 4E, shMMP13 did not change soluble amyloid-b 40/42 or insoluble amyloid-b 42 levels in wild-type mice, whereas insoluble amyloid-b 40 levels were significantly reduced. In APP/PS1 mice treated with shMMP13, the soluble and insoluble amyloid-b 40/42 levels were all significantly decreased. To determine whether BACE1 alterations caused by Mmp13 knockdown were associated with eIF4B activity, we assessed p-eIF4B levels. As shown in Fig. 4F , the basal levels of p-eIF4B were significantly higher in APP/PS1 mice than in wildtype mice, and shMMP13 significantly decreased p-eIF4B levels in wild-type and APP/PS1 mice. On the other hand, the protein levels of the amyloid-b degrading enzymes neprilysin and insulin-degrading enzyme (IDE) were not altered by shMMP13 in wild-type or APP/PS1 mice (Fig. 4E) . Interestingly, the levels of Iba1, a marker of inflammation, were also decreased in shMMP13-treated mice ( Supplementary Fig. 1 ). These results indicated that shMMP13 effectively reduced hippocampal BACE1 levels and amyloid-b generation in wild-type and APP/ PS1 mice, which was consistent with the altered levels of p-eIF4B.
Next, we assessed the effect of CL82198 on Alzheimer's disease-associated pathology. As shown in Fig. 5A , the administration of CL82198 for 2 months significantly decreased the number of amyloid-b plaques in APP/PS1 mice. Similar to Mmp13 knockdown, CL82198 reduced BACE1, sAPPb and b-CTF levels and increased sAPP levels in wild-type and APP/ PS1 mice without affecting APP, ADAM10 or PSEN1 levels (Fig. 5B) . CL98198 also mimicked the effect of shMMP13 on amyloid-b generation. Insoluble amyloid-b 40 levels were significantly decreased in wild-type mice, and soluble and insoluble amyloid-b 40/42 levels were significantly reduced in APP/ Figure 4 Mmp13 knockdown ameliorates Alzheimer's disease-associated pathology in APP/PS1 mice. (A) Representative western blots and bar plot summary of MMP13 and PI3K expression in the prefrontal cortex of control (n = 13) and Alzheimer's disease patients (n = 13). Data in (i and ii) and in (iii-v) were from samples provided by Sydney Brain Bank and NIH NeuroBiobank, respectively. (B) Immunohistochemical images and bar plot summary of neuritic plaques in the hippocampi of wild-type (WT) and APP/PS1 mice (AD) treated with vehicle (CTRL) and Mmp13 shRNA-1 (shMMP13-1). Neuritic plaques were probed with the amyloid-b-specific monoclonal antibody 6E10 (n = 6). (C) Representative western blots and bar plot summary of MMP13, APP, ADAM10, BACE1, PSEN1, bCTF, CTF, sAPPb and sAPP expression in the hippocampi of wild-type (n = 8), wild-type with Mmp13 shRNA-1 (WT-shMMP13-1, n = 8), Alzheimer's disease (n = 8) and Alzheimer's disease with Mmp13 shRNA-1 mice (AD-shMMP13-1, n = 8). The soluble fractions were used to detect sAPPb and sAPP with sAPPb and 6E10 antibodies. (D) Representative western blots and bar plot summary of MMP13 and BACE1 expression in the hippocampi of wild-type (n = 6), wild-type with Mmp13 shRNA-2 (WT-shMMP13-2, n = 6), Alzheimer's disease (n = 6) and Alzheimer's disease with Mmp13 shRNA-2 mice (AD-shMMP13-2, n = 6). (E) ELISAs were used to measure soluble and insoluble amyloid-b 40/42 levels in the brain homogenates of wild-type (n = 6), WT-shMMP13-1 (n = 6), Alzheimer's disease (n = 6) and AD-shMMP13-1 (n = 6) mice. (F) Representative western blots and bar plot summary of p-eIF4B, eIF4B, neprilysin and insulin-degrading enzyme (IDE) levels in the hippocampi of wild-type (n = 8), WT-shMMP13-1 (n = 8), Alzheimer's disease (n = 8) and AD-shMMP13-1 (n = 8) mice. All values were normalized to CTRL or wild-type (1.0) within each experiment. The error bars are the SEM. n.s. = no significant difference; *P 5 0.05, **P 5 0.01, ***P 5 0.001 (ANOVA).
PS1 mice (Fig. 5C) . Moreover, CL82198 similarly decreased peIF4B levels in wild-type and APP/PS1 mice without affecting neprilysin or IDE levels (Fig. 5D) . CL82198 also reduced Iba1 levels in APP/PS1 mice ( Supplementary Fig. 1 ). These results indicated that CL82198 mimicked the effect of MMP13 knockdown on Alzheimer's disease-associated pathology. bar plot summary of neuritic plaques in the hippocampi of wild-type, wild-type with CL82198 (WT-CL), APP/PS1 (AD) and APP/PS1 mice treated with CL82198 (AD-CL) (n = 6). (B) Representative western blots and bar plot summary of MMP13, APP, ADAM10, BACE1, PSEN1, bCTF, CTF, sAPPb and sAPP levels in the hippocampi of wild-type (n = 8), WT-CL (n = 8), AD (n = 8) and AD-CL (n = 8) mice. Soluble fractions were used to detect sAPPb and sAPP with sAPPb and 6E10 antibodies. (C) ELISAs were used to measure soluble and insoluble amyloid-b 40/42 levels in the brain homogenates of wild-type (n = 6), WT-CL (n = 6), AD (n = 6) and AD-CL (n = 6) mice. (D) Representative western blots and bar plot summary of p-eIF4B, eIF4B, neprilysin and IDE levels in the hippocampi of wild-type (n = 8), WT-CL (n = 8), AD (n = 8) and AD-CL (n = 8) mice. All values were normalized to CTRL or wild-type (1.0) within each experiment. The error bars are the SEM. n.s. = no significant difference; *P 5 0.05, **P 5 0.01, ***P 5 0.001 (ANOVA). Ab = amyloid-b.
CL82198 treatment or Mmp13 knockdown improves cognitive function in APP/PS1 mice To determine whether CL82198 or MMP13 may affect cognitive functions, we assessed spatial and associative learning memory using water maze tests and context fear conditioning tests in animals with Mmp13 knockdown or CL82198 treatment (Ly et al., 2013; Webster et al., 2014) . In the hidden platform test, the escape latency was significantly shorter in CL82198-treated APP/PS1 [Alzheimer's disease (AD)-CL] mice than in saline-treated APP/PS1 (Alzheimer's disease) mice beginning on the third day (Fig. 6A) . When the platform was removed during the probe trial, the passing time for crossing over the target site (Fig. 6B ) and the staying time in the target quadrant (Fig. 6C) were significantly longer in AD-CL mice than in Alzheimer's disease mice. No significant differences were observed between AD-CL and wild-type mice receiving CL82198 (WT-CL) or saline (wild-type, WT) for escape latency (Fig. 6A ), passing times (Fig. 6B ) or staying times (Fig. 6C) . The subsequent context fear conditioning tests revealed that AD-CL mice exhibited more and longer freezing times than Alzheimer's disease mice ( Fig. 6D and E) . No significant differences were observed between WT-CL and wild-type mice for their number of freezing times (Fig.  6D) or length of freezing times (Fig. 6E) . These results indicated that CL82198 significantly improved spatial and associative learning memory in APP/PS1 mice.
Hippocampal Mmp13 knockdown had effects similar to CL82198 for the water maze test (Fig. 6F-H) . In the fear conditioning test, while the freezing times were significantly greater in AD-shMMP13-1 mice than in Alzheimer's disease mice, the difference was not significantly different ( Fig. 6I and J) . These results supported that MMP13 mediated the effect of CL82198 on behavioural activities in an animal model.
Discussion
The function of MMP13 in the CNS is not well understood. Studies suggest that MMP13 is involved in tumour progression (Kobayashi et al., 2012; Guan et al., 2015; Zheng et al., 2015) and membrane permeability of brain endothelial cells (Lu et al., 2009) . Our study provides evidence that MMP13 controls BACE1 protein levels in multiple cell lines and primary cultured neurons (Fig. 1) .
MMP13 is known to degrade ECM components, such as type I-IV collagen and perlecan (Leeman et al., 2002; Yurchenco, 2011) . Perlecan is a heparin sulphate proteoglycan that is capable of binding a variety of growth factors (Iozzo et al., 2009) . It has been suggested that heparin plays an important role in receptor dimerization, which enables the autophosphorylation of the receptor cytoplasmic tail (Schlessinger et al., 2000) . The involvement of RTK-PI3K signalling in MMP13 function has been documented. For example, RTK/PI3K mediates MMP13's regulation of prostate cancer invasion (Lin et al., 2016) and myeloma metastasis (Xu et al., 2015) . Mmp13 knockdown inhibits the growth factor-induced proliferation of melanocytes (Meierjohann et al., 2010) . In line with these data, our study provides evidence that MMP13 increases PI3K activity and p-Akt levels, and these effects are prevented by an RTK inhibitor. As RTK or PI3K inhibitors reduce basal BACE1 protein levels and further diminish the effect of MMP13/CL82198 on BACE1 (Fig. 2) , we speculate that PI3K signalling is essential for the MMP13 regulation of BACE1.
PI3K signalling plays an important role in Alzheimer's disease pathology (O' Neill, 2013) . Enhanced PI3K activity is associated with disrupted autophagic clearance of amyloid-b and tau (Heras-Sandoval et al., 2014) . However, how PI3K might regulate BACE1 processing is currently unclear. It is unlikely that PI3K might regulate BACE1 through transcriptional regulation and protein degradation (Fig. 2) . Alternatively, PI3K might achieve translational control of BACE1 through eIF4B. PI3K is known to increase eIF4B phosphorylation at S422 through the S6 kinase (S6K) (Raught et al., 2004; Holz et al., 2005) . S6K and the p90 ribosomal protein S6 kinase (RSK) phosphorylate eIF4B at the same residue, which promotes eIF4B interaction with eIF3 and translation (Shahbazian et al., 2006 (Shahbazian et al., , 2010 . In our study, the overexpression or knockdown of MMP13 enhanced or reduced eIF4B phosphorylation at S422, respectively (Fig. 3) , supporting that eIF4B activity might bridge PI3K signalling with the MMP13-mediated regulation of BACE1.
At the translational level, BACE1 can be regulated by eIF2, but conflicting results have been reported. While one study shows that the phosphorylation of eIF2 increases BACE1 protein levels and amyloid-b production (O'Connor et al., 2008) , another reveals that eIF2 deficiency does not result in BACE1 inhibition in mice (Sadleir et al., 2014) . To the best of our knowledge, the involvement of eIF4B in BACE1 translation has not been previously reported. eIF4B phosphorylation at S422 is essential for cap-dependent translation (Shahbazian et al., 2006; van Gorp et al., 2009) . In addition, eIF4B is unique in that it selectively regulates long and structured 5 0 UTR function (Dmitriev et al., 2003) , while being insufficient for ribosomal movement on unstructured 5 0 UTRs (Pestova and Kolupaeva, 2002) . Interestingly, the BACE1 5 0 UTR is GC-rich and structured (Lammich et al., 2004; Rossner et al., 2006) . Thus, it is plausible that eIF4B phosphorylation might play a role in BACE1 translation. In our study, the following findings indicate that eIF4B is critical in MMP13 0 s regulation of BACE1: (i) in cells overexpressing the eIF4B mutant S422R, CL82198-induced inhibition or MMP13-induced increases in BACE1 protein levels were diminished ( Fig. 3E and F) ; and (ii) the inhibition of BACE1 protein expression by S422R or CL82198 occurred only when the BACE1 5 0 UTR was present ( Fig. 3G and H) .
MMP13 is upregulated in the brains of rats and humans after cerebral ischaemia (Cuadrado et al., 2009 ). In our study, MMP13 expression was increased in patients with Alzheimer's disease and APP/PS1 mice, suggesting that MMP13 also plays an important role in the pathology of Alzheimer's disease (Graham et al., 2017) . In line with these data, Mmp13 knockdown reduces BACE1, sAPPb and b-CTF protein levels, with a concomitant increase in Figure 6 CL82198 treatment or Mmp13 knockdown improves learning and memory in APP/PS1 mice. Behavioural performance was assessed by Morris water maze tests followed by fear conditioning tests. (A) In the hidden platform tests, the time spent on reaching the platform (latency) was recorded by ANY-maze tracking software. Compared with vehicle-treated APP/PS1 mice (AD, n = 10), CL82198 treated APP/PS1 mice (AD-CL, n = 10) showed a significantly shorter latency on the third, fourth and fifth days. No significant differences were found for the AD-CL mice or wild-type mice treated with vehicle (WT, n = 8) or CL82198 (WT-CL, n = 9). (B and C) In the probe trial on the sixth day, AD-CL mice spent significantly more time travelling (B) and a significantly longer time staying (C) in the place where the hidden platform was previously placed than Alzheimer's disease mice. (D and E) In the context fear conditioning tests, the freezing times and the total freezing times of the four groups of mice in the chamber were recorded and analysed after drug injection. (F) In the hidden platform tests, shMMP13-treated APP/ PS1 mice (AD-shMMP13-1, n = 7) exhibited a significantly shorter latency on the third, fourth and fifth days than the vehicle-treated APP/PS1 mice (AD, n = 9). No significant differences were found between AD-shMMP13-1 and wild-type mice treated with vehicle (WT, n = 7) or shMMP13 (WT-shMMP13-1, n = 6). (G and H) On the sixth day of the probe trial, AD-shMMP13-1 mice spent significantly more time travelling (G) and a significantly longer time staying (H) in the place where the hidden platform was previously placed than the Alzheimer's disease mice. (I and J) In the context fear conditioning tests, the freezing times and the total freezing times of the four groups of mice in the chamber were recorded and analysed for mice treated with shMMP13 or vehicle. All values were normalized to wild-type (1.0) within each experiment. The error bars are the SEM. n.s. = no significant difference; *P 5 0.05, **P 5 0.01, ***P 5 0.001 (ANOVA).
sAPP. The latter might be a secondary effect of BACE1 inhibition because sAPP can be increased after BACE1 inhibition (Fukumoto et al., 2010) . Notably, Mmp13 knockdown significantly reduced insoluble amyloid-b 40 , but not amyloid-b 42 levels in wild-type mice, while soluble and insoluble amyloid-b 40/42 levels were decreased in APP/ PS1 mice. Although it has been reported that BACE1 deficiency reduces both amyloid-b 40 and amyloid-b 42 levels (Ohno et al., 2004) , there is evidence showing that BACE1 inhibition preferentially reduces amyloid-b 40 levels in the mouse brain or in mouse cell lines (Ohno et al., 2004; Herzig et al., 2007; Fukumoto et al., 2010) . In a mouse model of Alzheimer's disease with an APP mutation, the partial inhibition of BACE1 results in reduced total amyloid-b levels, whereas amyloid-b 42 levels remain unchanged (McConlogue et al., 2007) . We speculate that the slight but significant inhibition of BACE1 might be responsible for the selective decrease in amyloid-b 40 levels in wild-type mice. On the other hand, APP/PS1 mice differ from wild-type mice in APP and PSEN1 mutations (Kurt et al., 2001) . While APP mutations dramatically increase ($50%) amyloid-b 40 levels without altering amyloid-b 42 levels (Morel et al., 2013) , mutations of g-secretase favour the generation of amyloid-b 42 over amyloid-b 40 (Jankowsky et al., 2004; Mastrangelo et al., 2005) . Thus, combined mutations in APP and PS1 lead to enhanced basal levels of amyloid-b 40 and amyloid-b 42 in APP/PS1 mice, in which inhibiting BACE1 reduces both amyloidb 40 and amyloid-b 42 levels (Ly et al., 2013) . Interestingly, Iba1 staining was also decreased in shMMP13/CL82198-treated mice (Supplementary Fig. 1 ). This effect might have been a result of the reduced amyloid-b load, since amyloid-b is neurotoxic and promotes inflammation (Sengupta et al., 2016) .
The role of MMP13 in Alzheimer's disease pathology was further supported by the results of behavioural tests in our study, as Mmp13 knockdown or CL82198 treatment improved spatial and associative learning memory (Fig. 6) . It was noted that Mmp13 knockdown and CL82198 treatment had different effects on freezing times (Fig. 6E versus Fig. 6J ). shMMP13-1 was introduced into only the hippocampus, while CL82198 was administered systematically. It has been reported that spatial learning (water maze) is critically dependent on the hippocampus (Neves et al., 2008) , whereas associative learning (fear conditioning) also involves the amygdala (Pape and Pare, 2010) . We speculate that one of the mechanisms contributing to the difference is that the amygdala was affected by CL82198 but was relatively spared from shMMP13-1.
We propose the following possible mechanisms by which MMP13 regulates BACE1 protein expression. The activation of PI3K signalling promotes eIF4B phosphorylation at S422, which leads to the 5 0 UTR-dependent translation of BACE1. According to this mechanism, CL82198 reduces BACE1 protein levels and amyloid-b accumulation, which contributes to the improved learning and memory in APP/ PS1 mice (Fig. 7) . It is worth noting that although MMP13-mediated regulation of BACE1 is dependent on PI3K signalling, the cognitive improvement by MMP13 inhibition in APP/PS1 mice may involve mechanisms beyond BACE1 and PI3K. It is suggested that ECM molecules play an important role in synaptic plasticity and control dendritic spines through the interaction with their receptors (Dansie and Ethell, 2011; Wlodarczyk et al., 2011) . ECM also mediates the crosstalk between neurons and glia in remodelling brain network function (Song and Dityatev, 2018) . In pathological conditions, accumulation of ECM components coincides with the synaptic dysfunction in APP/PS1 mice (Vegh et al., 2014) . Moreover, inhibition of MMP9 attenuates traumatic injury and behavioural impairment (Jia et al., 2014) . In line with this, the elevated MMP13 level in the ischaemic brain may suggest a role in neuronal damage (Cuadrado et al., 2009) . Therefore, the potential role of MMP13 in synaptic dysfunction or cellular stress requires further study.
The clinical relevance of the current study may include the following: (i) the study design provides an alternative strategy for BACE1 inhibitors: reducing BACE1 protein levels while allowing residual BACE1 to exert its function. To the best of our knowledge, luciferase-based drug screening for BACE1 in living cells has not been previously reported; (ii) the translational mechanism associated with MMP13 and PI3K signalling in BACE1 regulation adds to the understanding of why BACE1 protein levels rather than BACE1 mRNA levels are significantly increased in Alzheimer's disease patients; and (iii) furthermore, we found that MMP13 levels are significantly increased in both Alzheimer's disease patients and APP/PS1 mice. By inhibiting MMP13, which is closely associated with BACE1 regulation, CL82198 might have therapeutic potential for Alzheimer's disease.
